SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A decrease in the sales to Rs. 649.11 millions was observed for the quarter ended September 2021. The sales stood at Rs. 723.15 millions during the similar quarter previous year.Net profit of the cmpany stood at Rs. 128.40 millions for the quarter ended September 2021 a decline of -36.23% from Rs. 201.34 millions  in the same quarter last year.Operating profit for the quarter ended September 2021 decreased to 195.43 millions as compared to 303.78 millions of corresponding quarter ended September 2020.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 649.11 723.15 -10.24 1376.63 1337.20 2.95 2834.73 2473.54 14.60
Other Income 19.02 17.36 9.56 28.45 24.65 15.42 68.23 90.01 -24.20
PBIDT 195.43 303.78 -35.67 469.05 542.73 -13.58 1074.44 857.67 25.27
Interest 0.08 0.17 -52.94 0.16 0.60 -73.33 0.84 11.00 -92.36
PBDT 195.35 303.61 -35.66 468.89 542.13 -13.51 1073.60 846.67 26.80
Depreciation 22.91 21.55 6.31 45.59 42.73 6.69 89.32 88.14 1.34
PBT 172.44 282.06 -38.86 423.30 499.40 -15.24 984.28 758.53 29.76
TAX 44.04 80.72 -45.44 109.42 144.85 -24.46 274.16 178.98 53.18
Deferred Tax -0.76 -0.36 111.11 -0.52 2.68 -119.40 25.72 -14.91 -272.50
PAT 128.40 201.34 -36.23 313.88 354.55 -11.47 710.12 579.55 22.53
Equity 223.56 223.36 0.09 223.56 223.36 0.09 223.46 223.36 0.04
PBIDTM(%) 30.11 42.01 -28.33 34.07 40.59 -16.05 37.90 34.67 9.31

Advanced Enzyme Tech Share Price

329.70 5.30 (1.63%)
10-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1935.25
Dr. Reddys Labs. 1245.50
Cipla 1438.75
Zydus Lifesciences 1150.50
Lupin 2496.05
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: